Updates for Primary Care Clinicians; Pearls from the American Diabetes Association Scientific Sessions
Dr. Martin Abrahamson will discuss recent clinical trials presented at the 80th American Diabetes Association (ADA) Scientific Sessions Virtual Experience which took place from June 12-16, 2020. Dr. Abrahamson will highlight important updates including new data on SGLT2 inhibitors related to cardiovascular outcomes, renal outcomes, and their use in prediabetes and will also discuss the latest information on continuous glucose monitoring. Further, Dr. Abrahamson will walk learners through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated into these guidelines. After this meeting review, you will be equipped to optimally manage type 2 diabetes based on these guidelines and new findings.
Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 07/30/2020, and they are subject to change as new information is published.
Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Deaconess Medical Center
Health Sciences Clinical Professor
UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
Executive Director, UC Irvine Program in Medical Education for the Latino Community
UC Irvine School of Medicine
The following relevant financial relationships have been disclosed by faculty:
Martin J. Abrahamson, MD, FACP
Novo Nordisk (Advisory Board); AstraZeneca (Advisory Board)
Charles Vega, MD, FAAFP (Moderator)
No relevant financial relationships disclosed.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This program has been approved for 1.00 contact hour of continuing education, which includes 1.00 hour of pharmacology.
Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 3 out of the 4 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Merck & Co., Inc.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.